UNSPSC 51312602: Alcaftadine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H21N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7Z8O94ECSX. European Medicines Agency schedules alcaftadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB37833. The term ALCAFTADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 3, 2006, list 56). Most nations schedule alcaftadine under HS 29333990 and SITC 51574.

As of Q4 2014, ALCAFTADINE remains the US FDA Preferred Term for this commodity. Alcaftadine bears US NLM identifiers UMLS ID C2348241 and NCI Concept Code C72686. SMILES: CN1CCC(=C2C3=CC=CC=C3CCN4C2=NC=C4C=O)CC1.

UNSPSC 51312602 Alcaftadine is a Commodity code that captures individual pharmaceutical products procured by state and local health agencies, though recent opportunities posted under this code reflect broader pharmaceutical and drug-management procurement rather than alcaftadine specifically. State and local governments use codes in this family to source prescription medications, over-the-counter products, and related pharmaceutical supplies for public health programs, community health initiatives, and employee benefit plans. Issuing bodies include state health and human services departments, county health agencies, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions and facility types.

Recent activity shows solicitation originating from Florida county health departments, Texas state health agencies, and multistate purchasing cooperatives including Minnesota's MMCAP alliance. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a response deadline of July 26, 2023 (note: date discrepancy in source), with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's MMCAP office issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with a response deadline of March 26, 2026 and contract effectiveness of July 1, 2026. Geographic activity centers on Florida, Texas, Minnesota, and Oregon through cooperative purchasing. The code shows active procurement but limited recent opportunities specifically for alcaftadine as a standalone product line.